ADGRL4 and cancer: ELTD1 is involved in both of these pathways and is also of interest as a driver of myofibroblast formation which is being specifically targeted for fibrosis and cancer [59], ELTD1 is therefore an attractive therapeutic target for a number of pathologic conditions.